Clinical trial
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)
NCT07020819 is registered in ClinicalTrials.gov with Annexon, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of a Single Dose of Tanruprubart (Also Commonly Known as ANX005) in Participants With Guillain-Barré Syndrome (GBS) (FORWARD Study)
- Lead sponsor
- Annexon, Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 12, 2025
- Completion date
- June 30, 2028
- Enrollment
- 30 (estimated)
- Sites
- 13
Conditions
As the registry lists them; a condition with its own page is linked.